We have also demonstrated the broader in vivo benefits of HDAC6 inhibition using a CF mouse model carrying the F508del mutation that was crossed to Hdac6 null mice to form a CF mouse lacking Hdac6 expression (CF/Hdac6)12,13. Here, HDAC6 is linked to cystic fibrosis.